About ionis pharmaceuticals inc. - IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
IONS At a Glance
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, California 92010
| Phone | 1-760-931-9200 | Revenue | 943.71M | |
| Industry | Pharmaceuticals: Major | Net Income | -381,387,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 33.834% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,402 | |
| View SEC Filings |
IONS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.413 |
| Price to Book Ratio | 26.415 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -35.085 |
| Enterprise Value to Sales | 13.347 |
| Total Debt to Enterprise Value | 0.208 |
IONS Efficiency
| Revenue/Employee | 673,117.689 |
| Income Per Employee | -272,030.67 |
| Receivables Turnover | 14.286 |
| Total Asset Turnover | 0.289 |
IONS Liquidity
| Current Ratio | 3.826 |
| Quick Ratio | 3.814 |
| Cash Ratio | 3.426 |
IONS Profitability
| Gross Margin | 96.995 |
| Operating Margin | -40.445 |
| Pretax Margin | -40.224 |
| Net Margin | -40.414 |
| Return on Assets | -11.686 |
| Return on Equity | -70.795 |
| Return on Total Capital | -12.289 |
| Return on Invested Capital | -14.702 |
IONS Capital Structure
| Total Debt to Total Equity | 534.53 |
| Total Debt to Total Capital | 84.24 |
| Total Debt to Total Assets | 74.19 |
| Long-Term Debt to Equity | 441.878 |
| Long-Term Debt to Total Capital | 69.639 |